冠状动脉内乙酰胆碱激发试验的安全性及标准方案启示
该荟萃分析纳入16项研究共12,585例患者,评估冠状动脉内乙酰胆碱激发试验的安全性。主要并发症总体合并发生率为0.5%(95%CI:0.0%-1.3%),无死亡报告;采用当代心外膜痉挛诊断标准(≥90%直径缩减)的研究中发生率较高(1.0%;95%CI:0.3%-2.0%),而西方人群较低(0.0%;95%CI:0.0%-0.45%)。
要点
- 冠脉内乙酰胆碱激发试验总体安全,主要并发症发生率0.5%,无死亡报告。
- 采用≥90%直径缩减诊断标准的研究主要并发症发生率较高(1.0%)。
- 西方人群主要并发症发生率较低(0.0%),100μg与200μg最大剂量方案安全性相似。
核心结论
- 冠状动脉内乙酰胆碱激发试验用于当代心外膜和微血管痉挛诊断是安全的。
- 在主要表现心肌缺血和/或非阻塞性冠状动脉心肌梗死的西方人群中安全性记录优异。
研究设计与样本
- 荟萃分析共纳入16项研究、12,585例患者。
主要发现
- 主要并发症(死亡、心肌梗死、室性心动过速/颤动、休克)总体合并发生率为0.5%(95%CI:0.0%-1.3%),无死亡报告。
- 采用当代心外膜痉挛诊断标准(≥90%直径缩减)的研究中主要并发症合并发生率显著较高,为1.0%(95%CI:0.3%-2.0%)。
- 西方人群主要并发症合并发生率显著较低,为0.0%(95%CI:0.0%-0.45%)。
- 最大乙酰胆碱剂量100μg与200μg的激发方案间,心外膜痉挛阳性率和主要并发症发生率相似。
临床怎么用
- 冠状动脉内乙酰胆碱激发试验可用于心外膜和微血管痉挛的临床诊断,总体安全性良好。
- 采用≥90%直径缩减的当代诊断标准时需关注较高的主要并发症风险。
- 西方人群(主要表现心肌缺血和/或非阻塞性冠状动脉心肌梗死)中操作安全性记录优异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heterogeneity in diagnostic criteria and provocation protocols has posed challenges in understanding the safety of coronary provocation testing with intracoronary acetylcholine (ACh) for the contemporary diagnosis of epicardial and microvascular spasm. OBJECTIVES: We examined the safety of testing and subgroup differences in procedural risks based on ethnicity, diagnostic criteria, and provocation protocols. METHODS: PubMed and Embase were searched in November 2021 to identify original articles reporting procedural complications associated with intracoronary ACh administration. The primary outcome was the pooled estimate of the incidence of major complications including death, myocardial infarction, ventricular tachycardia/fibrillation, and shock. RESULTS: A total of 16 studies with 12,585 patients were included in the meta-analysis. The overall pooled estimate of the incidence of major complications was 0.5% (95% CI: 0.0%-1.3%) without any reports of death. Exploratory subgroup analyses revealed that the pooled incidence of major complications was significantly higher in the studies that followed the contemporary diagnosis criteria for epicardial spasm defined as ≥90% diameter reduction (1.0%; 95% CI: 0.3%-2.0%) but significantly lower in Western populations (0.0%; 95% CI: 0.0%-0.45%). The rate of positive epicardial spasm and the incidence of major complications were similar between provocation protocols using the maximum ACh doses of 100 μg and 200 μg. CONCLUSIONS: Intracoronary ACh administration for the contemporary diagnosis of epicardial and microvascular spasm is a safe procedure. Moreover, excellent safety records are observed in Western populations primarily presenting with myocardial ischemia and/or infarction with nonobstructive coronary arteries. This study will help standardize ACh testing to improve clinical diagnosis and ensure procedural safety.
引用
- Takahashi T, Samuels BA, Li W, et al. Safety of Provocative Testing With Intracoronary Acetylcholine and Implications for Standard Protocols. J Am Coll Cardiol. 2022. PMID: 35710187. doi:10.1016/j.jacc.2022.03.385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。